Fmr LLC Grows Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

FMR LLC boosted its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 4.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 2,916,494 shares of the company's stock after buying an additional 129,300 shares during the period. FMR LLC owned 2.57% of Centessa Pharmaceuticals worth $46,635,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. First Light Asset Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock valued at $43,168,000 after acquiring an additional 1,778,515 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 438.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after acquiring an additional 1,625,000 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock valued at $18,891,000 after acquiring an additional 987,997 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock valued at $35,518,000 after acquiring an additional 850,000 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $4,064,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CNTA shares. BMO Capital Markets raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research note on Monday, September 16th. Oppenheimer restated an "outperform" rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a "buy" rating and a $33.00 target price on the stock. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Trading Up 6.7 %

Shares of CNTA traded up $1.18 during trading hours on Friday, reaching $18.67. 690,784 shares of the company traded hands, compared to its average volume of 682,048. Centessa Pharmaceuticals plc has a 12-month low of $6.15 and a 12-month high of $18.77. The stock's fifty day moving average price is $16.41 and its 200 day moving average price is $13.00. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -12.20 and a beta of 1.52. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. Sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 16,619 shares of the business's stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total value of $260,752.11. Following the completion of the transaction, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 175,000 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the completion of the transaction, the chief executive officer now owns 776,924 shares of the company's stock, valued at $12,834,784.48. This represents a 18.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 462,624 shares of company stock valued at $7,763,698 over the last three months. 11.59% of the stock is owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.